PMC:7161517 / 3442-3770 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T12","span":{"begin":305,"end":308},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T34","span":{"begin":169,"end":192},"obj":"Disease"}],"attributes":[{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T24","span":{"begin":121,"end":124},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T25","span":{"begin":309,"end":312},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T26","span":{"begin":321,"end":322},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T31","span":{"begin":14,"end":28},"obj":"Chemical"},{"id":"T32","span":{"begin":18,"end":28},"obj":"Chemical"},{"id":"T33","span":{"begin":30,"end":44},"obj":"Chemical"},{"id":"T36","span":{"begin":30,"end":41},"obj":"Chemical"},{"id":"T37","span":{"begin":42,"end":44},"obj":"Chemical"},{"id":"T38","span":{"begin":75,"end":92},"obj":"Chemical"},{"id":"T39","span":{"begin":102,"end":113},"obj":"Chemical"},{"id":"T40","span":{"begin":305,"end":308},"obj":"Chemical"}],"attributes":[{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A34","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A35","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_25354"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T10","span":{"begin":279,"end":289},"obj":"http://purl.obolibrary.org/obo/GO_0065007"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":169,"end":192},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T99","span":{"begin":18,"end":28},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T100","span":{"begin":30,"end":44},"obj":"CHEBI:48432;CHEBI:48432;DG_37"},{"id":"T101","span":{"begin":45,"end":62},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T102","span":{"begin":75,"end":92},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T103","span":{"begin":93,"end":113},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T104","span":{"begin":169,"end":183},"obj":"UBERON:0004535"},{"id":"T105","span":{"begin":239,"end":243},"obj":"G_3;PG_10;PR:000003622"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}

{"project":"LitCovid-PubTator","denotations":[{"id":"112","span":{"begin":14,"end":17},"obj":"Gene"},{"id":"113","span":{"begin":75,"end":101},"obj":"Gene"},{"id":"114","span":{"begin":239,"end":243},"obj":"Gene"},{"id":"147","span":{"begin":169,"end":192},"obj":"Disease"}],"attributes":[{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"Gene:1636"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"Gene:4306"},{"id":"A114","pred":"tao:has_database_id","subj":"114","obj":"Gene:59272"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases. In the last 2 decades, the identification of ACE2 and its involvement in the counter regulation of the classic RAS has offered a poten"}